PubMed Health⌕ Search

Biomedical subjects

D Latinne

Publications and source records attributed to D Latinne.

At least 91 records · Page 5Linked to original sources
PubMed1992

Hepatic localization of a fibrosarcoma in a child with a liver transplant.

Two years after an orthotopic liver transplantation, a multifocal hepatic tumor with lymphonodular metastases, identified as a fibrosarcoma, developed in a 4-year-old girl being treated with cyclosporine. On a needle biopsy sample, genetic typing of the HLA-DR group revealed that tumoral cells were from the recipient.

Child, Preschool↗
PubMed1992

ABO-incompatible orthotopic liver allografting in urgent indications.

The influence of ABO-compatibility was reviewed in 70 emergency orthotopic hepatic transplantations (OHT) performed at our institution in 60 highly urgent recipients between February 1984 and March 1989. Thirty-eight were ABO-identical (Id); 16, compatible (Comp), and 16, incompatible (Inc) transplants, respectively. The three groups did not differ statistically with respect to the indications, the adult/child ratio and the proportions of first OHT and retransplantations. Graft survival rates of ABO-Id, ABO-Comp and ABO-Inc OHT at one year were 47, 38 and 19 per cent, respectively (p less than 0.02). Incidences of perioperative mortality, arterial thrombosis and irreversible rejection were slightly (although not significantly) higher in the ABO-Inc group. Retransplantation rates were 19, 7 and 36 per cent in the ABO-Id, Comp and Inc groups, respectively. Patient survival rates at one year were 59 per cent for the ABO-Id group versus 43 per cent for both ABO-Comp and Inc combinations (NS). The results of this series of highly urgent OHT confirm that graft survival is lower with ABO-Inc livers; their use should be strictly considered as a short term life-saving procedure. Improvement of patient survival after a first urgent ABO-Inc OHT may require an aggressive policy of retransplantation.

ABO Blood-Group System↗
PubMed1991

Bone marrow transplantation in sickle cell anaemia.

Sickle cell anaemia is still responsible for severe crippling and death in young patients living in developing countries. Apart from prophylaxis and treatment of infections, no active treatment can be safely proposed in such areas of the world. Therefore a bone marrow transplantation was performed in 12 patients staying in Belgium and planning to return to Africa. Twelve patients, aged between 11 months and 23 years (median 4 years), underwent a HLA identical bone marrow transplantation. The conditioning regimen included oral busulphan for four consecutive days (4 mg/kg) followed by four days of intravenous cyclophosphamide (50 mg/kg). In 10 patients the engraftment was rapid and sustained. A further patient suffered transient red cell hypoplasia and another underwent a second bone marrow transplantation from the same donor at day 62 because of graft rejection. All patients are alive and well with a follow up ranging from 9-51 months (median 27 months). In all cases a complete cessation of vaso-occlusive episodes and haemolysis was observed as was a change in the haemoglobin pattern in accordance with the donor's electrophoretic pattern.

Adolescent↗
PubMed1991

Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission.

One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than 56 years were allocated to receive either allogeneic (allo-BMT) or autologous bone marrow transplantation (auto-BMT) when first complete remission (CR1) was achieved. CR was obtained in 96 patients. Twenty-four patients had an HLA-identical sibling donor and 20 of these (83%) had an allograft in CR1. Thirty-three patients (44% of the CR1 patients without donor) had an autograft in CR1. The reasons for not transplanting patients in CR1 were early relapse (nine patients), refusal (11 patients) or medical problems (23 patients). The 4-year leukemia-free survival (LFS) probability for all the CR1 patients was 25%. For the allo-BMT patients, the 4-year LFS was 71%, and for the auto-BMT patients 31% (log-rank p = 0.028). The relapse probabilities were 33% and 48% respectively (p = 0.40). If the results are analysed according to the intent of the protocol, patients with a donor had an LFS of 53%, and patients without a donor an LFS of 16% (p = 0.003). This study confirms the value of allo-BMT for consolidation of ANL in CR1. The attempt to autograft all CR1 patients without a compatible donor has not resulted in any marked improvement of LFS.

Adult↗
PubMed1989

[Leukocyte immunization and early spontaneous abortions].

Forty patients who had had at least two early spontaneous abortions, i.e. before the 12th week of pregnancy without known aetiology factors (anatomical, chromosomal, infectious or hormonal) were immunised with their husband's leucocytes. These immunisations were carried out by repeated intravenous injections of leucocytes taken from the husband's peripheral blood. In 24 patients the search for anti-HLA antibodies was shown to be positive after a varying number of injections (2 to 10). Twelve patients are still being treated, 4 did not make antibodies. Eighteen pregnancies have been observed, of whom 11 have so far come to term, 4 are following a normal course and 3 pregnancies were interrupted late of different reasons. The success rate, by which is meant pregnancies without early abortion, was 17/21, i.e. 81%. A comparison of the number of HLA A, B or DR antigens found to be shared between the couple in 40 couples studied, when compared with a series of 64 fertile couples (who had had at least 2 children without any abortions) shows no differences. These couples as compared with fertile couples do not show either differences in the frequency of HLA antigens. After leucocyte immunisation an inhibition in the mixed lymphocyte culture is found between the patient's lymphocytes and her husband's in the wife's serum if this has made anti-HLA antibodies.

Abortion, Habitual↗